People living with Huntington’s Disease (HD) and their families are asking Congress to stand with them at a critical moment. After decades without any treatment that slows or stops this devastating disease, a gene therapy called AMT-130 by uniQure is showing unprecedented promise — offering people living with HD more time to work, care for their families, and remain independent. But the FDA’s current stance may prevent the therapy from moving forward to full review.

We need your voice.
Please urge your Members of Congress to contact the FDA and support allowing AMT-130 to be submitted for a Biologics License Application (BLA). This is not a request for shortcuts, only for a fair, science-driven review of all available data and continued dialogue as additional evidence emerges.

For people living with HD, time is not a luxury.
Your message today can help ensure that lifesaving innovation is not delayed unnecessarily and that hope remains within reach for thousands of people affected by HD.